Nuvalent, Inc. - Class A Common Stock (NUVL)

The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B).

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week.

Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each.

NUVL stock results show that Nuvalent missed analyst estimates for earnings per share the second quarter of 2024.

NUVL stock results show that Nuvalent missed analyst estimates for earnings per share the first quarter of 2024.

Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promising response rates in pretreated patients, with pivotal results expected in 2025.

Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test.

Although short-squeeze stocks to buy present great risk, betting against the bears can also yield dramatically robust returns.

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.

Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.

The dilution monster stalked the company following the announcement of a new capital-raising effort.

Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance to uncover new information.

The company reported preliminary data on a non-small cell lung cancer therapy.

Nuvalent announced favorable preliminary data in a clinical trial for its lung cancer drug. Here's what investors need to know.

Stifel initiated coverage on Nuvalent Inc (NASDAQ: NUVL), recognizing that adopting a bullish stance in anticipation of Phase 1 cancer drug data, mainly when derived from heavily pretreated patients, has proven unprofitable for approximately two years.